A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

NCT ID: NCT00606229

Last Updated: 2014-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2010-11-30

Brief Summary

To assess the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner in patients with Bipolar I Disorder experiencing a manic or mixed episode

Conditions

Bipolar I Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Aripiprazole

Intervention Type: DRUG

oral, 24mg/day

Interventions

Aripiprazole

oral, 24mg/day

Intervention Type: DRUG

Other Intervention Names

OPC-14597

Eligibility Criteria

Inclusion Criteria

• Trial subjects will be men and women of age 18 or above and below the age of 65 who will not be turning 65 during the trial.
• Patients have the ability to understand and to provide informed consent to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial.
• Patients who meet DSM-IV-TR criteria for manic or mixed episodes and have been diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"
• Patients with a YMRS total score of 16 or more

Exclusion Criteria

• Patients presenting with a clinical picture and/or history that is consistent with a DSM-IV-TR diagnosis of:

• Delirium, dementia, amnestic disorder, or other cognitive disorders
• Schizophrenia or other psychotic disorder
• Personality disorder
• Patients experiencing their first manic or mixed episode
• Patients whose current manic episode has lasted for more than 4 weeks
• Patients with psychotic symptoms that are clearly due to another general medical condition or direct physiological effects of a substance
• Patients who have met DSM-IV-TR criteria for a substance-related disorder within 3 months (90 days) prior to informed consent (excluding caffeine- and nicotine-related disorders, but including abuse of benzodiazepines)
• Patients who have received ECT treatment within 8 weeks prior to informed consent
• Patients who are expected to require administration of ultrashort-acting or short-acting benzodiazepine receptor agonist hypnotics and antianxiety drugs (See (1) of 4.2.2) at doses exceeding the equivalent of 15 mg/day of diazepam (Only for those patients using such drugs)
• Patients at significant risk of developing a severe adverse event. Patients who have a medical condition that would interfere with assessments of safety or efficacy during the course of the trial, or who have a history of such a condition.
• Patients who have received any of the following treatments during the screening period

• Reserpine
• Levodopa, dopamine receptor stimulants
• Monoamine oxidase inhibitors
• Psychostimulants
• Thyroid hormones, antithyroid drugs
• Corticosteroids (other than topical preparations)
• Adrenaline
• All other investigational or unapproved agents
• ECT
• Light therapy
• Patients judged to have a diabetic blood glucose level (judgment based on use of a self-monitoring blood glucose meter permissible), or patients whose HbA1c is 6.5% or higher
• Patients with a history or a complication of diabetes

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Katsuhisa Saito

Role: STUDY_DIRECTOR

Department of Clinical Research and Development, Division of New Product Evaluation and Development

Locations

Chugoku Region, , Japan

Hokuriku Region, , Japan

Kanto Region, , Japan

Kinki Region, , Japan

Shikoku Region, , Japan

Countries

Japan

Other Identifiers

031-07-001

Identifier Type: -

Identifier Source: org_study_id